Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-human Study to Assess the Safety and Feasibility of Intra-articular Administration of Allogeneic Engineered Gingival Fibroblasts (aeGF) in Patients With Knee Osteoarthritis

NCT06690710 is registered in ClinicalTrials.gov with Scarcell Therapeutics S.A.S. as lead sponsor.

NCT NCT06690710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06690710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-human Study to Assess the Safety and Feasibility of Intra-articular Administration of Allogeneic Engineered Gingival Fibroblasts (aeGF) in Patients With Knee Osteoarthritis
Lead sponsor
Scarcell Therapeutics S.A.S.
Phase
Phase 1
Overall status
Recruiting
Start date
August 14, 2025
Completion date
February 1, 2028
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis, knee